SFX by Ex Libris Inc.

Title:	Potent and selective inhibitors of gelatinase-a 1. hydroxamic acid derivatives
Source:	Bioorganic & Medicinal Chemistry Letters [0960-894X] Porter, John yr:1994

Basic

Full text

Full text available via Elsevier SD Backfile Medicine and Dentistry

Year:

Volume:

Issue:

Start Page:

Full text available via Elsevier SD Backfile Organic Chemistry

Year:

Volume:

Issue:

Start Page:

Full text available via Elsevier SD Backfile Pharmacology

Year:

Volume:

Issue:

Start Page:

Full text available via EZB-NALI5-00465 Elsevier Archive NL

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Neidle, S. "Chemical approaches to the discovery and development of cancer therapies." Nature reviews. Cancer 5.4 (2005): 285-96.
description	2.	van Erp, Nielka P. "Clinical pharmacokinetics of tyrosine kinase inhibitors." Cancer Treatment Reviews 35.8 (2009): 692-706.
description	3.	Peng, B. "Clinical pharmacokinetics of imatinib." Clinical pharmacokinetics 44.9 (2005): 879-94.
description	4.	Schindler, T. "Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase." Science 289.5486 (2000): 1938-1942.
description	5.	Sawyers, C L L. "Chronic Myeloid Leukemia." The New England journal of medicine 340.17 (1999): 1330-1340.
description	6.	Zimmermann, J. "(Phenylamino)pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors." Bioorganic & medicinal chemistry letters 6.11 (1996): 1221-1226.
description	7.	Capdeville, R. "Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug." Nature reviews. Drug discovery 1.7 (2002): 493-502.
description	8.	Manley, P W W. "Imatinib: a selective tyrosine kinase inhibitor." European journal of cancer 38.1005 (2002): 19-27.
description	9.	Beijnen, Jos H H. "Drug interactions in oncology." The lancet oncology 5.8 (2004): 489-96.
description	10.	van Harten, J. "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clinical pharmacokinetics 29.1 (1993): 203-220.
description	11.	Nagar, B. "Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)." Cancer research 62.15 (2002): 4236-43.
description	12.	Mazitschek, R. "Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases." Current opinion in chemical biology 8.4 (2004): 432-41.
description	13.	Faderl, S. "The biology of chronic myeloid leukemia." The New England journal of medicine 341.3 (1999): 164-72.
description	14.	Hehlmann, R. "Chronic myeloid leukaemia." Lancet, The 370.9584 (2007): 342-50.
description	15.	Deininger, M W W. "The molecular biology of chronic myeloid leukemia." Blood 96.10 (2000): 3343-56.
description	16.	Young, A M M. "Can pharmacokinetic monitoring improve clinical use of fluorouracil?" Clinical pharmacokinetics 36.6 (1999): 391-8.
description	17.	Lietha, D. "Structural basis for the autoinhibition of focal adhesion kinase." Cell 129.6 (2007): 1177-87.
description	18.	Deininger, M. "The development of imatinib as a therapeutic agent for chronic myeloid leukemia." Blood 105.7 (2005): 2640-53.
description	19.	Lydon, B J J. "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells." Nature medicine 2.5 (1996): 561-6.
description	20.	Abbott, R. "Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada." Journal of oncology pharmacy practice 20.1 (2013): 29-39.